Company Overview and News

134
Synergy: Can It Come Back?

18h seekingalpha
Synergy (SGYP) has been one of my of my most exasperating investments. I started small and wary last April when I wrote my first exploratory article. I doubled down several times and came to regret each one.
SGYP RAD SGYPW CIC

8
Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

2018-07-16 globenewswire
WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.
ABT SGYP SGYPW RDUS ABT

0
Synergy Pharmaceuticals: Partner, Merger, Ex-USA Deal Or Co-Promotion?

2018-07-13 seekingalpha
On or before August 9th Synergy Pharmaceuticals has committed to provide an update on their strategic business review.
SGYP SGYPW

3
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

2018-07-06 zacks
Investors in Synergy Pharmaceuticals Inc. (SGYP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $3.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
SGYP SGYPW ENPH

282
Time Is Nearly Up For Adamis

2018-06-19 seekingalpha
It has now been a year since the FDA approved Adamis' Symjepi epinephrine injector and still, no commercial partner has been confirmed.
SGYP SGYPW ADMP

244
Activist Group Strikes Down Key Proposals At Synergy Pharma

2018-06-18 seekingalpha
The collective activist group who controls more than 13% of the public float proved to be key in striking down shareholder unfriendly proposals.
SGYP SGYPW

309
Synergy Pharmaceuticals: At Last A Glimmer Of Hope?

2018-06-18 seekingalpha
Shareholders voted against the current board; they also voted down several proposals, including one to increase executive compensation and another that would have increased the number of authorized shares.
SGYP AGN SGYPW

360
Synergy Pharmaceuticals: Better Days Likely Ahead, But Better Opportunities Elsewhere

2018-06-13 seekingalpha
We look back at the flawed investment thesis we presented late last year and learn from our mistakes.
IRWD SGYP AGN CPHRF AIMT SGYPW NBIX MNK GBT FENCF CPHR FENC

267
SGYP / Synergy Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-12 sec.gov
Document UNITED STATES
SGYP

1281
The 6 Most Shorted Nasdaq Stocks

2018-06-12 247wallst
With one exception, the most shorted stocks traded on the Nasdaq in the two-week period that ended May 31 did not get a lot of action. That’s not terribly surprising given that the Nasdaq Composite Index rose by just 1.2% in the same period and volatility remained in check.
FOX OPK CELGZ CMCSA AMD SIRI MAT SGYP CZR MU CELG SGYPW CSCO NVCN INTC FOXA

306
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors

2018-06-12 globenewswire
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry.
SGYP CPRX OPNT SGYPW

316
The 'Joe Papa' Effect Is Arriving At Valeant

2018-06-11 seekingalpha
Investors quite often forget a key valuation component that can't be measured in any exact financial figure: management. Yet it has a significant effect on valuations.
SGYP MYL AGN PRGO SGYPW

313
Synergy Pharmaceuticals: CEO Troy Hamilton Is Very Capable - Will He Succeed?

2018-06-07 seekingalpha
Troy Hamilton, CEO of Synergy Pharmaceuticals has the necessary pharmaceutical experience to make Synergy a success story. It's now up to him to make peace with shareholders.
IRWD SGYP AGN SGYPW

573
Your Daily Pharma Scoop: Endra Zooms, Biogen And Eisai Present Positive Results, Synergy Moves Up

2018-06-07 seekingalpha
With just $7.8M market capitalization and 13 full-time employees, Endra Life Sciences (NASDAQ:NDRA) was part of all financial news sources yesterday when its stock prices jumped +58.1%. The company was incorporated in 2007 and offered its IPO in May 2017. The IPO was priced at $5 and is still close to the all-time high the stock price ever reached. At 3.50 pm June 4 the stock reached its recent nadir at $1.
TSRO IRWD ECYT AXSM VSTM NDRA LLY VKTX RA RTTR EXAS SGYP VKTXW RSLS HCC BIIB AGN VBLT WIZP ABBV WIZPD ABBV

SGYP: Synergy Pharmaceuticals Stock Analysis and Research Report

2017-09-29 - Asif

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide. TRULANCE (plecanatide) Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 871639308